ES2958118T3 - Derivado de dihidroindolizinona - Google Patents

Derivado de dihidroindolizinona Download PDF

Info

Publication number
ES2958118T3
ES2958118T3 ES19741238T ES19741238T ES2958118T3 ES 2958118 T3 ES2958118 T3 ES 2958118T3 ES 19741238 T ES19741238 T ES 19741238T ES 19741238 T ES19741238 T ES 19741238T ES 2958118 T3 ES2958118 T3 ES 2958118T3
Authority
ES
Spain
Prior art keywords
group
alkoxy
salt
alkyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19741238T
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ES2958118T3 publication Critical patent/ES2958118T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES19741238T 2018-01-18 2019-01-18 Derivado de dihidroindolizinona Active ES2958118T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018006269 2018-01-18
PCT/JP2019/001364 WO2019142883A1 (ja) 2018-01-18 2019-01-18 ジヒドロインドリジノン誘導体

Publications (1)

Publication Number Publication Date
ES2958118T3 true ES2958118T3 (es) 2024-02-01

Family

ID=67302218

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19741238T Active ES2958118T3 (es) 2018-01-18 2019-01-18 Derivado de dihidroindolizinona

Country Status (12)

Country Link
US (1) US11530211B2 (https=)
EP (1) EP3741757B1 (https=)
JP (1) JP7359697B2 (https=)
KR (1) KR20200110338A (https=)
CN (1) CN111630052B (https=)
AU (1) AU2019208634B2 (https=)
CA (1) CA3088968C (https=)
ES (1) ES2958118T3 (https=)
IL (1) IL276125A (https=)
SG (1) SG11202006837XA (https=)
TW (1) TWI818948B (https=)
WO (1) WO2019142883A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040966A (zh) * 2019-07-08 2022-02-11 国立大学法人东京工业大学 使用了二氢吲嗪酮衍生物的胰岛素生产细胞的制作法
EP4727939A1 (en) * 2023-06-14 2026-04-22 Prothena Biosciences Limited 5-(cinnolin-6-yl)thiazole compounds for treating neurological disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
JP2003128551A (ja) 2001-08-15 2003-05-08 Sankyo Co Ltd 新規抗糖尿病医薬組成物
EP2239328A3 (en) 2005-08-18 2011-01-05 Alnylam Pharmaceuticals Inc. Methods and compositions for treating neurological disease
EP1999253B1 (en) 2006-03-02 2019-05-22 Viacyte, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
EP2373645A4 (en) * 2008-12-08 2012-05-02 Sirtris Pharmaceuticals Inc ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS
WO2012056997A1 (ja) 2010-10-28 2012-05-03 国立大学法人熊本大学 多能性幹細胞の分化誘導効率を改善するための方法及び培地
JPWO2012121168A1 (ja) 2011-03-04 2014-07-17 国立大学法人京都大学 キナーゼ阻害剤
AU2013255031C1 (en) 2012-04-30 2018-12-06 University Health Network Methods and compositions for generating pancreatic progenitors and functional beta cells from hPSCs
JP2014161257A (ja) 2013-02-22 2014-09-08 Univ Of Tokyo 多能性幹細胞から膵ランゲルハンス島を製造する方法
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
DK3039122T3 (da) 2013-08-30 2019-09-30 Novo Nordisk As Generering af endokrine progenitorceller fra humane pluripotente stamceller under anvendelse af små molekyler
WO2015125662A1 (ja) 2014-02-21 2015-08-27 国立大学法人熊本大学 アミノ酸組成変更培地を用いた幹細胞の分化促進方法、及び該方法を用いて処理された幹細胞、並びに培地
JP6094516B2 (ja) 2014-03-19 2017-03-15 三菱電機株式会社 エレベーター装置
US10006006B2 (en) 2014-05-16 2018-06-26 Janssen Biotech, Inc. Use of small molecules to enhance MAFA expression in pancreatic endocrine cells
US10457916B2 (en) 2014-05-20 2019-10-29 Tokyo Institute Of Technology Method for inducing differentiation of insulin-producing cells
CN107001356B (zh) * 2014-07-31 2019-09-03 默克专利有限公司 用于神经退化性疾病的中氮茚衍生物
WO2016100898A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived b cells and uses thereof
CN107614678B (zh) 2014-12-18 2021-04-30 哈佛学院校长同事会 干细胞来源的β细胞的产生方法及其使用方法
WO2016100909A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
WO2016100921A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College METHODS FOR GENERATING STEM CELL-DERIVED β CELLS AND USES THEREOF
US20160177268A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating augmented stem cell-derived beta cells and uses thereof
CA2979293C (en) 2015-03-11 2022-01-04 Timothy J. Kieffer Pancreatic endocrine progenitor cell therapies for the treatment of obesity and type 2 diabetes (t2d)

Also Published As

Publication number Publication date
AU2019208634A1 (en) 2020-08-06
EP3741757A4 (en) 2021-11-03
CN111630052B (zh) 2023-04-18
CA3088968A1 (en) 2019-07-25
TW201938156A (zh) 2019-10-01
CA3088968C (en) 2023-10-17
EP3741757B1 (en) 2023-07-26
AU2019208634A2 (en) 2020-09-24
US20210053965A1 (en) 2021-02-25
CN111630052A (zh) 2020-09-04
IL276125A (en) 2020-08-31
AU2019208634B2 (en) 2024-06-13
TWI818948B (zh) 2023-10-21
SG11202006837XA (en) 2020-08-28
JPWO2019142883A1 (ja) 2021-01-14
US11530211B2 (en) 2022-12-20
JP7359697B2 (ja) 2023-10-11
EP3741757A1 (en) 2020-11-25
WO2019142883A1 (ja) 2019-07-25
KR20200110338A (ko) 2020-09-23

Similar Documents

Publication Publication Date Title
KR101471999B1 (ko) Ｇｓｋ-3 저해제
JP2018062535A (ja) ガンの治療方法
JP5747142B2 (ja) Ｄｙｒｋを阻害する化合物を含有する医薬組成物
TW201114765A (en) Use of aminodihydrothiazines for the treatment or prevention of diabetes
CA2723233A1 (en) Specific inhibitors for vascular endothelial growth factor receptors
CN102844023A (zh) Cdc7激酶抑制剂以及其用途
CA2986930A1 (en) Chemical modulators of signaling pathways and therapeutic use
EP4431498A1 (en) Novel oxadiazole derivative and use thereof
ES2958118T3 (es) Derivado de dihidroindolizinona
KR20240019078A (ko) 포도막 흑색종을 치료하기 위한 우레아 유도체
JP2022528155A (ja) 糖尿病ならびに膵臓機能障害に関連する他の病気の治療のための選択的ｆｏｘｏ阻害剤
HK40031650B (en) Dihydroindolizinone derivative
Brown et al. The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3 (4H)-yl] benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases
HK40031650A (en) Dihydroindolizinone derivative
JP7553030B2 (ja) ジヒドロインドリジノン誘導体を用いたインスリン産生細胞の作製法
WO2023201014A1 (en) Benzothiazole-phenylsulfonyl-piperidine analogs as activators of n-acylphosphatidylethanolamine hydrolyzing phospholipase d
HK40066575A (en) Method for producing insulin-producing cell using dihydroindolizinone derivatives
KR102789906B9 (ko) 신규 피리미딘 유도체
KR101048748B1 (ko) 신규 갈바닉산 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
WO2024140653A1 (zh) 选择性cdk12/13抑制剂及其应用